COVID-19 vaccines — $1.9T BioNTech / $5.2T total enabled by open-genome publication

On January 10-11, 2020, the SARS-CoV-2 genome was shared publicly via virological.org and GISAID. BioNTech's Project Lightspeed launched January 27, 2020 — 17 days later, with eight vaccine candidates designed within 48 hours of the founders' decision. Pfizer joined the partnership on March 17, 2020.

The resulting Pfizer-BioNTech vaccines generated an estimated $1.9 trillion in global economic value, part of $5.2 trillion across all COVID-19 vaccines (S-0113).

The case is the strongest single demonstration of the time dimension of the open-data multiplier. The 17-day lag between public genome publication and vaccine candidate generation was operationally possible only because the genome was shared openly and unconditionally. A regime in which the genome had been shared under standard restrictive licensing or held internally would have produced a different vaccine timeline measured in months or quarters rather than days.

For the AI-era extension developed in §10 (C-0033), the same architectural property — open, content-addressed, distributed scientific data — is what enables the timescale-of-discovery acceleration AI research depends on. The COVID case is the proof of concept for what Tier 3 + open access can deliver at planetary scale.